tetano
Editor, Senior Moderator
Clin Exp Vaccine Res
. 2025 Apr;14(2):169-184.
doi: 10.7774/cevr.2025.14.e20. Epub 2025 Apr 8. New-onset hematologic disorders following COVID-19 vaccination: a systematic review
Nelson Luis Cahuapaza-Gutierrez[SUP] 1 2 [/SUP], Cielo Cinthya Calderon-Hernandez[SUP] 1 2 [/SUP], Renzo Pajuelo-Vasquez[SUP] 1 2 [/SUP], Helya Yusara Coronado-Quispe[SUP] 1 [/SUP], Milagros Altamirano-Molina[SUP] 3 4 [/SUP], Fernando M Runzer-Colmenares[SUP] 2 [/SUP], Tatiana Vanessa Villavicencio-Escudero[SUP] 1 [/SUP]
Affiliations
Purpose: Coronavirus disease 2019 (COVID-19) vaccination reduced morbimortality rates due to severe acute respiratory syndrome coronavirus 2 infection worldwide. However, various complications have been reported, including hematologic disorders.
Materials and methods: We conducted a systematic review to synthesize and analyze the current available evidence on the development of hematological disorders associated with COVID-19 vaccination.
Results: A total of 227 patients were reported in the papers that were selected to be included. There was a slight predominance of females (n=114, 50.22%) compared to males (n=113, 49.78%), and the calculated mean age was 54.86±18.94 years. The most frequently reported hematological disorders were Immune thrombocytopenic purpura (n=58, 25.55%), followed by thrombotic thrombocytopenic purpura (n=38, 16.74%). The less frequently recorded cases were acquired factor XIII/13 deficiency (n=2, 0.88%) and pernicious anemia (n=2, 0.88%). Messenger RNA (mRNA)-based COVID-19 vaccines, including Pfizer BioNTech 162b2 (n=106, 46.70%), Moderna mRNA 127-3 (n = 42, 18.50%), and the Bivalent vaccine (n = 1, 0.44%), were the most prevalent (n=150, 66.08%). Most cases developed after the first dose (n=120, 52.86%). In most cases, patient outcomes were favorable (n=175, 77.09%), but there were significant mortality cases (n=23, 10.13%).
Conclusion: Our findings suggest close monitoring of patients who receive the first dose with mRNA technology vaccines, regardless of sex, especially in adults, as they appear more vulnerable to developing hematologic disorders.
Trial registration: PROSPERO Identifier: CRD42023452589.
Keywords: Blood diseases; COVID-19 vaccines; Hematologic diseases; SARS-CoV-2 vaccines; Systematic review.
. 2025 Apr;14(2):169-184.
doi: 10.7774/cevr.2025.14.e20. Epub 2025 Apr 8. New-onset hematologic disorders following COVID-19 vaccination: a systematic review
Nelson Luis Cahuapaza-Gutierrez[SUP] 1 2 [/SUP], Cielo Cinthya Calderon-Hernandez[SUP] 1 2 [/SUP], Renzo Pajuelo-Vasquez[SUP] 1 2 [/SUP], Helya Yusara Coronado-Quispe[SUP] 1 [/SUP], Milagros Altamirano-Molina[SUP] 3 4 [/SUP], Fernando M Runzer-Colmenares[SUP] 2 [/SUP], Tatiana Vanessa Villavicencio-Escudero[SUP] 1 [/SUP]
Affiliations
- PMID: 40321788
- PMCID: PMC12046088
- DOI: 10.7774/cevr.2025.14.e20
Purpose: Coronavirus disease 2019 (COVID-19) vaccination reduced morbimortality rates due to severe acute respiratory syndrome coronavirus 2 infection worldwide. However, various complications have been reported, including hematologic disorders.
Materials and methods: We conducted a systematic review to synthesize and analyze the current available evidence on the development of hematological disorders associated with COVID-19 vaccination.
Results: A total of 227 patients were reported in the papers that were selected to be included. There was a slight predominance of females (n=114, 50.22%) compared to males (n=113, 49.78%), and the calculated mean age was 54.86±18.94 years. The most frequently reported hematological disorders were Immune thrombocytopenic purpura (n=58, 25.55%), followed by thrombotic thrombocytopenic purpura (n=38, 16.74%). The less frequently recorded cases were acquired factor XIII/13 deficiency (n=2, 0.88%) and pernicious anemia (n=2, 0.88%). Messenger RNA (mRNA)-based COVID-19 vaccines, including Pfizer BioNTech 162b2 (n=106, 46.70%), Moderna mRNA 127-3 (n = 42, 18.50%), and the Bivalent vaccine (n = 1, 0.44%), were the most prevalent (n=150, 66.08%). Most cases developed after the first dose (n=120, 52.86%). In most cases, patient outcomes were favorable (n=175, 77.09%), but there were significant mortality cases (n=23, 10.13%).
Conclusion: Our findings suggest close monitoring of patients who receive the first dose with mRNA technology vaccines, regardless of sex, especially in adults, as they appear more vulnerable to developing hematologic disorders.
Trial registration: PROSPERO Identifier: CRD42023452589.
Keywords: Blood diseases; COVID-19 vaccines; Hematologic diseases; SARS-CoV-2 vaccines; Systematic review.